Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will present a corporate presentation at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026 in San Francisco.

Presentation details: Date: January 11, 2026; Time: 1:20 PM PT; Presenter: Laxminarayan Bhat, Ph.D.; Location: Marines’ Memorial Club, San Francisco, CA.

Key Figures

Forum date January 11, 2026 Sachs 9th Annual Neuroscience Innovation Forum presentation date

Presentation time 1:20 PM PT Scheduled time for Reviva corporate presentation

Current share price $0.3069 Price before the Sachs forum announcement

52‑week range $0.25 – $2.17 Pre‑news 52‑week low and high

Market Reality Check

$0.3400 Last Close

Volume Volume 7,732,483 is slightly below the 20‑day average of 8,224,779 (relative volume 0.94x) ahead of this forum update. normal

Technical Shares at 0.3069 are trading below the 200‑day MA of 0.62 and remain far under the 2.17 52‑week high.

Peers on Argus

Momentum scanner shows no coordinated sector move. Nearby biotech peers show mixed single‑day changes (e.g., KZR +0.16%, TENX +0.88%, NEUP -2.11%, LSB -20.62%, OKUR -2.10%), suggesting RVPH’s action was more stock‑specific than driven by a broad CNS/biotech rotation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	Regulatory update	Negative	-45.5%	FDA asked for a second Phase 3 brilaroxazine trial before NDA filing.
Nov 13	Earnings and update	Positive	-6.6%	Q3 2025 results, positive OLE data, and capital raises alongside NDA planning.
Nov 12	Data presentation	Positive	+3.3%	Neuroscience 2025 presentation on anti‑inflammatory effects of brilaroxazine.
Nov 10	Patent grant	Positive	+9.1%	European patent granted for brilaroxazine use in pulmonary fibrosis.
Oct 29	Investor conference	Neutral	+1.7%	Participation in Spartan Capital investor conference to highlight the story.

Pattern Detected

Recent major clinical and regulatory updates have triggered large directional moves, with the negative FDA feedback on brilaroxazine prompting the sharpest selloff, while positive IP and data presentations saw supportive but smaller gains.

Recent Company History

Over the last few months, Reviva has reported several material milestones. A Dec 23, 2025 FDA regulatory update on brilaroxazine required a second Phase 3 trial, and the stock fell 45.54%. Earlier, Q3 2025 results on Nov 13, 2025 included a net loss of $4.0M, cash of $13.2M, and recent equity raises. November also brought new schizophrenia and anti‑inflammatory data presentations and a European patent for pulmonary fibrosis, which produced modestly positive reactions. An investor conference on Oct 29, 2025 had a small upside impact. Today’s forum presentation fits into this pattern of ongoing visibility efforts alongside pivotal regulatory and financing needs.

Market Pulse Summary

The stock moved -5.4% in the session following this news. A negative reaction despite neutral conference news fits a pattern where RVPH has occasionally sold off around broader disclosures, such as the sharp -45.54% move after the FDA requested a second Phase 3 study. In that context, weakness around a non‑data presentation could reflect lingering concerns from recent regulatory and financing updates rather than this event alone, especially given prior going‑concern language and capital‑structure changes.

Key Terms

central nervous system medical

"developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

cardiometabolic medical

"unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. Not financial advice.

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9^th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial Club, San Francisco, CA

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

When will Reviva (RVPH) present at the Sachs 9th Annual Neuroscience Innovation Forum?

Reviva will present on January 11, 2026 at 1:20 PM PT.

Who is presenting for Reviva (RVPH) at the January 11, 2026 forum?

Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will deliver the corporate presentation.

What is the format and location of Reviva's (RVPH) presentation on January 11, 2026?

The presentation is a corporate presentation at the Marines’ Memorial Club in San Francisco, CA.

How can investors attend Reviva's (RVPH) Sachs forum presentation on January 11, 2026?

The announcement lists the in‑person presentation at the Marines’ Memorial Club; further access details were not provided.

What topics will Reviva (RVPH) cover at the Sachs Neuroscience Innovation Forum?

The company announced a corporate presentation but did not specify presentation topics in this notice.